DGAP-Ad-hoc: BRAIN Biotech AG / Key word(s): Miscellaneous 
BRAIN Biotech AG: First Development Phase for a novel Genome Editing Tool Completed (CRISPR Cas) 
06-May-2021 / 17:54 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
BRAIN Biotech AG: First Development Phase for a novel Genome Editing Tool Completed (CRISPR Cas) 
Zwingenberg, Germany 
May 6^th, 2021 
BRAIN Biotech AG ("BRAIN") has successfully completed the first development phase for a novel genome editing tool based 
on a Non-Cas9 nuclease. It has been validated as a genome editing tool and the tool has been demonstrating DNA 
targeting activity in selected bacteria, fungi and yeast. Activity in plants has been achieved but still needs to be 
validated. Further potential beyond selected microorganisms and plants is currently being explored. A first IP 
application to protect the nuclease sequence was submitted. The tool is expected to give BRAIN freedom to operate for 
internal as well as customer projects and could provide significant economic upside from commercializing the technology 
if the next development steps prove to be successful and a patent is granted. 
Notifying person: 
Michael Schneiders, Head of IR & Sustainability 
BRAIN Biotech AG 
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany 
www.brain-biotech.com 
Investor Relations Office 
Tel.: +49-(0)-6251-9331-0 
Fax: +49-(0)-6251-9331-11 
E-Mail: ir@brain-biotech.com 
=---------------------------------------------------------------------------------------------------------------------- 
Information and Explanation of the Issuer to this News: 
About BRAIN 
BRAIN Biotech AG ('BRAIN') is a leading European specialist in industrial biotechnology. As a technology provider and 
developer of bio-based products and solutions for nutrition, health and the environment, the company supports the 
biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN 
Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned 
industrial partners as well as an incubator for the development of the company's own highly innovative products. In the 
BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, 
microorganisms and bioactive natural products and the respective distribution. 
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises 
microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology 
portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already 
successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, 
which together with the associated biotechnological production expertise, complete the value chain within the Group. 
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN 
DE0005203947 / WKN 520394). 
=---------------------------------------------------------------------------------------------------------------------- 
06-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      BRAIN Biotech AG 
              Darmstädter Straße 34-36 
              64673 Zwingenberg 
              Germany 
Phone:        +49 (0) 62 51 / 9331-0 
Fax:          +49 (0) 62 51 / 9331-11 
E-mail:       ir@brain-biotech.com 
Internet:     www.brain-biotech.com 
ISIN:         DE0005203947 
WKN:          520394 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1193623 
 
End of Announcement  DGAP News Service 
=------------

1193623 06-May-2021 CET/CEST


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1193623&application_name=news

(END) Dow Jones Newswires

May 06, 2021 11:56 ET (15:56 GMT)